Analysts Issue Forecasts for Disc Medicine FY2028 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Equities researchers at Wedbush lifted their FY2028 EPS estimates for Disc Medicine in a note issued to investors on Wednesday, October 22nd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $1.79 for the year, up from their previous estimate of $1.64. Wedbush has a “Outperform” rating and a $110.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, August 7th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.41).

Several other equities research analysts have also issued reports on IRON. Cantor Fitzgerald lifted their price objective on shares of Disc Medicine from $132.00 to $153.00 and gave the company an “overweight” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday. Morgan Stanley lifted their price objective on shares of Disc Medicine from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Monday, August 18th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Thursday, July 3rd. Finally, Truist Financial assumed coverage on shares of Disc Medicine in a research note on Monday, July 21st. They issued a “buy” rating and a $86.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.70.

Disc Medicine Stock Up 2.3%

IRON stock opened at $85.63 on Friday. The company has a current ratio of 32.11, a quick ratio of 32.11 and a debt-to-equity ratio of 0.05. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $95.95. The company has a fifty day simple moving average of $66.30 and a 200 day simple moving average of $56.40. The firm has a market cap of $2.98 billion, a PE ratio of -19.16 and a beta of 0.80.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Arizona State Retirement System increased its holdings in shares of Disc Medicine by 12.5% during the 1st quarter. Arizona State Retirement System now owns 5,315 shares of the company’s stock worth $264,000 after purchasing an additional 590 shares during the period. Amalgamated Bank increased its holdings in shares of Disc Medicine by 38.6% during the 1st quarter. Amalgamated Bank now owns 787 shares of the company’s stock worth $39,000 after purchasing an additional 219 shares during the period. Northern Trust Corp increased its holdings in shares of Disc Medicine by 11.7% during the 1st quarter. Northern Trust Corp now owns 208,813 shares of the company’s stock worth $10,365,000 after purchasing an additional 21,796 shares during the period. Atle Fund Management AB bought a new stake in Disc Medicine in the second quarter valued at about $1,306,000. Finally, MetLife Investment Management LLC increased its stake in Disc Medicine by 10.9% in the first quarter. MetLife Investment Management LLC now owns 13,454 shares of the company’s stock valued at $668,000 after acquiring an additional 1,322 shares during the period. Institutional investors own 83.70% of the company’s stock.

Insider Activity

In other news, Director Kevin Bitterman sold 71,961 shares of the business’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $70.58, for a total transaction of $5,079,007.38. Following the transaction, the director owned 500,621 shares in the company, valued at approximately $35,333,830.18. The trade was a 12.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 226,933 shares of company stock worth $17,005,801. Insiders own 3.64% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.